COVID-19-associated coagulopathy: a concise review on pathogenesis and clinical implications.

Memar Montazerin, Sahar; Najafi, Homa; Shojaei, Fahimehalsadat; Chi, Gerald; Goudarzi, Sogand; Sharfaei, Sadaf; Kahe, Farima; Hassanzadeh, Shakiba

In this review, we summarize the possible mechanisms of COVID-19-associated coagulopathy and compare its features to other similar conditions. The recent COVID-19 pandemic has caused enormous mortality and morbidity worldwide. It is important to note that COVID-19-associated thrombotic events play a huge role in the morbidity of this disease. Interestingly, it has been observed that this complication may occur despite prophylactic anticoagulant therapy. Recent studies on COVID-19-associated coagulopathy revealed that the COVID-19-associated hypercoagulability is more frequently observed among those with a severe course of the disease. Various mechanisms have been suggested as explanations for this condition and possible underlying etiologies.